Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 4Recruiting 3Completed 2Withdrawn 1Not yet recruiting 1Enrolling by invitation 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 6Genitourinary 5Breast 3Plasma cell 2Gastrointestinal 2Tumor-Agnostic 1Thoracic 1Sarcoma 1Myeloid 1Lymphoid 1Gynecologic 1Endocrine 1

Conditions

Insulinoma 1Hyperinsulinism 1Congenital Hyperinsulinism 1

Interventions

telotristat ethyl 4lutetium Lu 177 dotatate 43-Iodobenzylguanidine 3vandetanib 2pasireotide 2gallium Ga 68 dotatate 2Temozolomide 2Octreotide 2Biological Therapy 2177Lu-octreotide, DOTA(0)-Tyr(3)- 2veliparib 1vatalanib 1trametinib 1pembrolizumab 1lanreotide 1fosbretabulin 1farletuzumab 1dabrafenib 1combretastatin 1ceritinib 1antineoplaston AS 2-1 1antineoplaston A10 1Tretinoin 1Tranexamic Acid 1Solutions 1Saline Solution 1Panitumumab 1Paclitaxel 1Microarray Analysis 1Isotretinoin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Injections × Endocrine × Clear all
NCT03053284 2021-05-14

Pasireotide in Hyperinsulinemic Hypoglycemia

Montefiore Medical Center

Phase 2 Withdrawn
Endocrine

Hyperinsulinism, Insulinoma, Congenital Hyperinsulinism

Data powered by HemOnc (CC BY 4.0) Colophon âš¡